First Manhattan’s Vanda Pharmaceuticals VNDA Stock Holding History

First Manhattan’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$411	–	1307
2024 Q1	$411	Hold	100	–	–	﹤0.01%	1357
2023 Q4	$422	Hold	100	–	–	﹤0.01%	1365
2023 Q3	$432	Sell	100 -1,000	-91%	-$5.56K	﹤0.01%	1382
2023 Q2	$7.25K	Hold	1,100	–	–	﹤0.01%	1184
2023 Q1	$7.47K	Hold	1,100	–	–	﹤0.01%	1246
2022 Q4	$8.13K	Hold	1,100	–	–	﹤0.01%	1297
2022 Q3	$10K	Hold	1,100	–	–	﹤0.01%	1214
2022 Q2	$11K	Buy	1,100 +1,000	+1,000%	+$10.4K	﹤0.01%	1216
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	1562
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	1548
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	1568
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	1512
2021 Q1	$1K	Hold	100	–	–	﹤0.01%	1450
2020 Q4	$1K	Hold	100	–	–	﹤0.01%	1312
2020 Q3	$0	Hold	100	–	–	﹤0.01%	1466
2020 Q2	$1K	Hold	100	–	–	﹤0.01%	1359
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	1349
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	1281
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	1301
2019 Q2	$1K	Sell	100 -379,304	-100%	-$6.04M	﹤0.01%	1343
2019 Q1	$6.98M	Sell	379,404 -559,970	-60%	-$12.8M	0.04%	204
2018 Q4	$24.5M	Buy	939,374 +113,999	+14%	+$2.68M	0.15%	91
2018 Q3	$18.9M	Sell	825,375 -131,491	-14%	-$2.68M	0.1%	128
2018 Q2	$18.2M	Buy	956,866 +956,666	+478,333%	+$16M	0.11%	132
2018 Q1	$3K	Hold	200	–	–	﹤0.01%	1304
2017 Q4	$3K	Hold	200	–	–	﹤0.01%	1368
2017 Q3	$3K	Hold	200	–	–	﹤0.01%	1347
2017 Q2	$3K	Hold	200	–	–	﹤0.01%	1308
2017 Q1	$2K	Hold	200	–	–	﹤0.01%	1342
2016 Q4	$3K	Hold	200	–	–	﹤0.01%	1301
2016 Q3	$3K	Hold	200	–	–	﹤0.01%	1318
2016 Q2	$2K	Hold	200	–	–	﹤0.01%	1408
2016 Q1	$1K	Hold	200	–	–	﹤0.01%	1366
2015 Q4	$1K	Hold	200	–	–	﹤0.01%	1384
2015 Q3	$2K	Hold	200	–	–	﹤0.01%	1363
2015 Q2	$2K	Hold	200	–	–	﹤0.01%	1381
2015 Q1	$1K	Hold	200	–	–	﹤0.01%	1417
2014 Q4	$2K	Hold	200	–	–	﹤0.01%	1411
2014 Q3	$2K	Hold	200	–	–	﹤0.01%	1385
2014 Q2	$3K	Hold	200	–	–	﹤0.01%	1329
2014 Q1	$3K	Hold	200	–	–	﹤0.01%	1308
2013 Q4	$2K	Hold	200	–	–	﹤0.01%	1303
2013 Q3	$2K	Hold	200	–	–	﹤0.01%	1301
2013 Q2	$1K	Buy	+200	New	+$1.35K	﹤0.01%	1334

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan's VNDA Position: Q2 2024 in Review

First Manhattan sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 100 shares — an estimated $411 sold.

First Manhattan first reported a position in VNDA in Q2 2013 and held it in 44 quarters. The position peaked at $24.5M in Q4 2018. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

First Manhattan reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 100 Vanda Pharmaceuticals shares in Q2 2024, an estimated $411.
First Manhattan first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 44 quarters.
First Manhattan's Vanda Pharmaceuticals position peaked at $24.5M in Q4 2018.
148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.